Semaglutide vs Tirzepatide: Weight Loss, Dosing & Head-to-Head Data

Semaglutide and tirzepatide are the two most-prescribed incretin therapies for weight loss — and as of 2025 there is finally a direct head-to-head trial separating them. This guide compares them in plain language: mechanism, the SURMOUNT-5 results, weight-loss magnitude, dosing, side effects, and how to think about choosing one over the other. For the single-agent deep dives, see What Is Semaglutide? and What Is Tirzepatide?.

The Short Answer

In the first head-to-head randomized trial (SURMOUNT-5, NEJM 2025), tirzepatide produced significantly greater weight loss than semaglutide — about 20.2% vs 13.7% of body weight at 72 weeks. Tirzepatide is a dual GLP‑1/GIP agonist; semaglutide is a GLP‑1‑only agonist. Tirzepatide tends to win on weight-loss magnitude, while semaglutide has the longer track record and landmark cardiovascular-outcomes data (SELECT). Both are once-weekly subcutaneous injections, both require slow dose titration, and both work best alongside diet and activity. (NEJM — SURMOUNT-5, NEJM — SELECT)

Mechanism: One Incretin Pathway vs Two

The core difference is how many incretin receptors each drug activates.

• Semaglutide is a GLP‑1 receptor agonist. It mimics glucagon‑like peptide‑1 to suppress appetite, slow gastric emptying, stimulate glucose‑dependent insulin secretion, and reduce glucagon output. Half-life ≈7 days. (STEP 1 — NEJM)
• Tirzepatide is a dual GLP‑1 + GIP receptor agonist (a "twincretin"). It engages the GLP‑1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway, which appears to amplify GLP‑1's metabolic effects and add an energy-expenditure component. Half-life ≈5 days. (Tirzepatide — NCBI)

That extra GIP arm is the leading explanation for why tirzepatide tends to out-perform semaglutide on weight and HbA1c at comparable time points. If you want the broader drug-class background, see What Is a GLP‑1?.

Side-by-Side Snapshot

Headline figures: STEP 1, SURMOUNT-1 efficacy, SURMOUNT-5 head-to-head.

The Head-to-Head: SURMOUNT-5

For years the comparison rested on cross-trial math — semaglutide's ~15% in STEP 1 versus tirzepatide's ~21% in SURMOUNT-1 — which is suggestive but not a fair fight, because the trials enrolled different people under different protocols. SURMOUNT-5 changed that. It was the first randomized, direct comparison of the two drugs in adults with obesity (without type 2 diabetes), run over 72 weeks across 32 U.S. and Puerto Rico sites (n≈751). (NEJM — SURMOUNT-5)

Key results:

• Weight loss: tirzepatide −20.2% vs semaglutide −13.7% of body weight (roughly 22.8 kg vs 15.0 kg). Tirzepatide was statistically superior on the primary endpoint.
• Waist circumference: −18.4 cm (tirzepatide) vs −13.0 cm (semaglutide).
• Tolerability: most adverse events were GI and occurred during dose escalation. Interestingly, GI side effects leading to discontinuation were less frequent with tirzepatide (2.7%) than semaglutide (5.6%).

The takeaway: for raw weight-loss magnitude, tirzepatide has the edge in a fair, randomized comparison — and at least in this trial it was not won by trading away tolerability.

Where Semaglutide Still Leads

Bigger average weight loss is not the only axis that matters.

• Cardiovascular outcomes. The SELECT trial (17,604 adults with overweight/obesity plus established CVD) showed semaglutide 2.4 mg cut major adverse cardiovascular events by 20% versus placebo — the first obesity drug to demonstrate a hard cardiovascular benefit. Tirzepatide's dedicated CV-outcomes trials are still maturing. (SELECT — NEJM)
• Track record. Semaglutide has been in wide clinical use since 2017 and has the deeper long-term safety dataset.
• Oral option. Semaglutide is available as an oral tablet (Rybelsus); tirzepatide is injection-only.

So if cardiovascular risk reduction is the primary goal, or an oral route matters, semaglutide remains a strong — sometimes better — choice.

Dosing & Titration

Both drugs are once-weekly subcutaneous injections, and both demand a "start low, go slow" titration to manage nausea and GI effects.

• Semaglutide (Wegovy): 0.25 mg/wk → 0.5 → 1.0 → 1.7 → 2.4 mg, stepping up about every 4 weeks. For research-compound reconstitution math, see the SEMA 5 mg Dosage Protocol and the semaglutide dosage calculator.
• Tirzepatide: 2.5 mg/wk for 4 weeks, then +2.5 mg every 4 weeks as tolerated, to a 15 mg maximum. See the Tirzepatide 10 mg Dosage Protocol and the tirzepatide dosage calculator.

Both share a class boxed warning for thyroid C‑cell tumors and are contraindicated in people with a personal/family history of medullary thyroid carcinoma or MEN2. (Semaglutide FDA label, Tirzepatide — NCBI)

Which Should You Choose?

A practical framing:

• Maximize weight loss → tirzepatide has the head-to-head edge (SURMOUNT-5).
• Proven cardiovascular benefit, or longest safety record → semaglutide (SELECT).
• Want a pill, not an injection → oral semaglutide (Rybelsus).
• Sensitive to GI side effects → individual response varies; SURMOUNT-5 actually saw fewer GI-driven discontinuations on tirzepatide, but titration speed matters more than the molecule for most people.

Neither is a substitute for diet, activity, and medical supervision — and for either drug, stopping treatment typically leads to substantial weight regain. The newest frontier is the triple agonist retatrutide; see Retatrutide vs Tirzepatide and What Is Retatrutide?.

FAQ

Is tirzepatide better than semaglutide for weight loss?
In the SURMOUNT-5 head-to-head trial, tirzepatide produced significantly greater weight loss than semaglutide — about 20.2% vs 13.7% of body weight at 72 weeks. So for raw weight-loss magnitude, tirzepatide has the edge. "Better" overall still depends on your goal: semaglutide has proven cardiovascular-outcome data (SELECT) and a longer track record. (NEJM — SURMOUNT-5)

What is the main difference between semaglutide and tirzepatide?
Semaglutide activates one incretin receptor (GLP‑1). Tirzepatide activates two (GLP‑1 and GIP), which is why it is called a "twincretin" or dual agonist. The added GIP activity is the leading explanation for tirzepatide's greater weight and blood-sugar effects in clinical trials. (Tirzepatide — NCBI)

Do semaglutide and tirzepatide have the same side effects?
Both are dominated by gastrointestinal effects — nausea, diarrhea, constipation — that are worst during dose escalation and improve over time. Both carry a class boxed warning for thyroid C‑cell tumors and gallbladder risk with rapid weight loss. In SURMOUNT-5, GI side effects causing discontinuation were less frequent with tirzepatide (2.7%) than semaglutide (5.6%). (NEJM — SURMOUNT-5)

Which one is better for the heart?
Semaglutide has the stronger cardiovascular evidence today. In the SELECT trial, semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in people with obesity and established cardiovascular disease. Tirzepatide's dedicated cardiovascular-outcomes trials are still ongoing. (SELECT — NEJM)

Can you switch from semaglutide to tirzepatide?
Switching is common in clinical practice, often to break a weight-loss plateau or for tolerability reasons. It should be done under medical supervision, restarting titration at tirzepatide's lowest dose (2.5 mg) rather than matching the previous semaglutide dose. Dosing of the two drugs is not interchangeable milligram-for-milligram.

Are semaglutide and tirzepatide the same as Ozempic and Mounjaro?
Semaglutide is the active ingredient in Ozempic (diabetes) and Wegovy (weight management). Tirzepatide is the active ingredient in Mounjaro (diabetes) and Zepbound (weight management). The brand differs by approved indication and dose, but the molecule within each pair is the same.

Next Steps

For reconstitution math and dosing tables, see the SEMA 5 mg and Tirzepatide 10 mg protocols, or run the numbers in the peptide dosage calculator. To see how the next-generation triple agonist compares, read Retatrutide vs Tirzepatide and Semaglutide vs Retatrutide.

Bottom line: tirzepatide leads on weight-loss magnitude in the only head-to-head trial to date; semaglutide leads on cardiovascular evidence and track record. Match the drug to the goal, and titrate slowly either way.